Effects of cisatracurium on epithelial‑to‑mesenchymal transition in esophageal squamous cell carcinoma

Lv,Wenyan; Wang,Jingyu; Zhang,Shubao

doi:10.3892/ol.2019.10859

Effects of cisatracurium on epithelial‑to‑mesenchymal transition in esophageal squamous cell carcinoma

Authors:
- Wenyan Lv
- Jingyu Wang
- Shubao Zhang
View Affiliations

Affiliations: Department of Anesthesiology, Chinese People's Liberation Army No. 117 Hospital, Hangzhou, Zhejiang 310013, P.R. China
Published online on: September 12, 2019 https://doi.org/10.3892/ol.2019.10859
Pages: 5325-5331
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive types of cancer worldwide, with a poor prognosis. The aim of the present study was to investigate the effect of cisatracurium (Cis) on epithelial‑to‑mesenchymal transition (EMT) in ESCC and its potential mechanism of action. In the present study, Cis was used to treat ECA‑109 cells, with cell proliferation measured by a Cell Counting Kit‑8 assay and the expression of TGF‑β and phospho‑Smad2/3 detected by western blotting. TGF‑β was then applied to induce EMT. Flow cytometry, wound healing and Transwell assays were used to evaluate cell proliferation, apoptosis, invasion and migration. In addition, cell cycle‑related proteins, including cyclin D1, p53 and p21, and EMT‑associated proteins, including E‑cadherin (E‑cad), N‑cadherin (N‑cad), Vimentin and Slug, were examined by western blot analysis. The results revealed that Cis inhibited the proliferation and promoted apoptosis of ESCC cells. Following treatment with Cis, the expression of TGF‑β and phosphorylation of Smad2/3 were downregulated. Cis also suppressed cancer cell invasion and migration induced by TGF‑β. In addition, the expression levels of cyclin D1 were decreased, accompanied by increased p53 and p21 expression. In addition, the expression level of E‑cad was increased, whereas N‑cad, Vimentin and Slug were significantly reduced. Taken together, the results of the present study revealed that exposure of ESCC cells to Cis inhibited EMT and reduced cell invasion and metastasis through the TGF‑β/Smad signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	D'Amico TA: Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res. 1:188–196. 2007.PubMed/NCBI
4	Dotto GP and Rustgi AK: Squamous cell cancers: A unified perspective on biology and genetics. Cancer Cell. 29:622–637. 2016. View Article : Google Scholar : PubMed/NCBI
5	Suo C, Yang Y, Yuan Z, Zhang T, Yang X, Qing T, Gao P, Shi L, Fan M, Cheng H, et al: Alcohol intake interacts with functional genetic polymorphisms of aldehyde dehydrogenase (ALDH2) and alcohol dehydrogenase (ADH) to increase esophageal squamous cell cancer risk. J Thorac Oncol. 14:712–725. 2019. View Article : Google Scholar : PubMed/NCBI
6	Yang PW, Hsieh MS, Chang YH, Huang PM and Lee JM: Genetic polymorphisms of ATG5 predict survival and recurrence in patients with early-stage esophageal squamous cell carcinoma. Oncotarget. 8:91494–91504. 2017.PubMed/NCBI
7	Cheng YW, Liao LD, Yang Q, Chen Y, Nie PJ, Zhang XJ, Xie JJ, Shan BE, Zhao LM, Xu LY and Li EM: The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cell Biochem Funct. 36:398–407. 2018. View Article : Google Scholar : PubMed/NCBI
8	Kastan MB, Canman CE and Leonard CJ: P53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev. 14:3–15. 1995. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R and Magnuson NS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells. Int J Biochem Cell Biol. 42:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI
10	Huang H, Han Y, Yang X, Li M, Zhu R, Hu J, Zhang X, Wei R, Li K and Gao R: HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway. Oncotarget. 8:103364–103374. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ghasri P, Admani S, Petelin A and Zachary CB: Treatment of actinic cheilitis using a 1,927-nm thulium fractional laser. Dermatol Surg. 38:504–507. 2012. View Article : Google Scholar : PubMed/NCBI
12	Quan J, Elhousiny M, Johnson NW and Gao J: Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclasts. Clin Exp Metastasis. 30:659–670. 2013. View Article : Google Scholar : PubMed/NCBI
13	Creighton CJ, Chang JC and Rosen JM: Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kang Y and Massague J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
15	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bai X, Li YY, Zhang HY, Wang F, He HL, Yao JC, Liu L and Li SS: Role of matrix metalloproteinase-9 in transforming growth factor-β1-induced epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Onco Targets Ther. 10:2837–2847. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhang C, Hao Y, Wang Y, Xu J, Teng Y and Yang X: TGF-β/SMAD4-regulated LncRNA-LINP1 inhibits epithelial-mesenchymal transition in lung cancer. Int J Biol Sci. 14:1715–1723. 2018. View Article : Google Scholar : PubMed/NCBI
18	Li F, Shi J, Xu Z, Yao X, Mou T, Yu J, Liu H and Li G: S100A4-MYH9 Axis promote migration and invasion of gastric cancer cells by inducing TGF-β-mediated epithelial-mesenchymal transition. J Cancer. 9:3839–3849. 2018. View Article : Google Scholar : PubMed/NCBI
19	Wu X, Zhao J, Ruan Y, Sun L, Xu C and Jiang H: Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer. Cell Death Dis. 9:11022018. View Article : Google Scholar : PubMed/NCBI
20	Jiang A, Zhao H, Cai J and Jiang WG: Possible effect of muscle-relaxant anaesthetics on invasion, adhesion and migration of breast cancer cells. Anticancer Res. 36:1259–1265. 2016.PubMed/NCBI
21	Xu YB, Du QH, Zhang MY, Yun P and He CY: Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci. 17:2486–2494. 2013.PubMed/NCBI
22	Jiang A, Zhao H, Liu X, Yu M, Chen J and Jiang WG: Comparison of different muscle-relaxant anesthetics on growth, migration and invasion of gastric cancer cells. Anticancer Res. 37:4371–4378. 2017.PubMed/NCBI
23	Yabasin IB, Sanches JGP, Ibrahim MM, Huidan J, Williams W, Lu ZL and Wen Q: Cisatracurium retards cell migration and invasion upon upregulation of p53 and inhibits the aggressiveness of colorectal cancer. Front Physiol. 9:9412018. View Article : Google Scholar : PubMed/NCBI
24	Yabasin IB, Lu Z and Yu JC: Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro. Biomed Pharmacother. 43:320–329. 2017. View Article : Google Scholar
25	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
26	Matsuda S, Takeuchi H, Kawakubo H, Ando N and Kitagawa Y: Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. Ann Thorac Cardiovasc Surg. 22:275–283. 2016. View Article : Google Scholar : PubMed/NCBI
27	Baba Y, Watanabe M, Yoshida N and Baba H: Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol. 6:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ciechanowicz SJ and Ma D: Anaesthesia for oncological surgery-can it really influence cancer recurrence? Anaesthesia. 71:127–131. 2016. View Article : Google Scholar : PubMed/NCBI
29	Santamaria LB, Schifilliti D, La Torre D and Fodale V: Drugs of anaesthesia and cancer. Surg Oncol. 19:63–81. 2010. View Article : Google Scholar : PubMed/NCBI
30	Besson A, Dowdy SF and Roberts JM: CDK inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI
31	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
32	Santarius T, Shipley J, Brewer D, Stratton MR and Cooper CS: A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 10:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
33	Shen G, Xu C, Chen C, Hebbar V and Kong AN: p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol. 57:317–327. 2006. View Article : Google Scholar : PubMed/NCBI
34	Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X and Lin W: Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett. 14:6829–6832. 2017.PubMed/NCBI
35	Huang X, Qiao Y, Zhou Y, Ruan Z, Kong Y, Li G, Xie X and Zhang J: Ureaplasma spp. Lipid-associated membrane proteins induce human monocyte U937 cell cycle arrest through p53-independent p21 pathway. Int J Med Microbiol. 308:819–828. 2018. View Article : Google Scholar : PubMed/NCBI
36	Wang Y, Qiu C, Lu N, Liu Z, Jin C, Sun C, Bu H, Yu H, Dongol S and Kong B: FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. Int J Oncol. 52:2130–2142. 2018.PubMed/NCBI
37	Liu L, Liu H, Zhou Y, He J, Liu Q, Wang J, Zeng M, Yuan D, Tan F, Zhou Y, et al: HLTF suppresses the migration and invasion of colorectal cancer cells via TGF β/SMAD signaling in vitro. Int J Oncol. 53:2780–2788. 2018.PubMed/NCBI
38	Liu Y, Wang JX, Huang D, Wang B, Li LL, Li XX, Ni P, Dong XL, Xia W, Yu CX, et al: PMLIV overexpression promotes TGF-β-associated epithelial-mesenchymal transition and migration in MCF-7 cancer cells. J Cell Physiol. 233:9575–9583. 2018. View Article : Google Scholar : PubMed/NCBI
39	Li L, Lv Y and Yan D: Inhibition of Ep3 attenuates migration and promotes apoptosis of non-small cell lung cancer cells via suppression of TGF-β/Smad signaling. Oncol Lett. 16:5645–5654. 2018.PubMed/NCBI
40	Luo D, Xu X, Li J, Chen C, Chen W, Wang F, Xie Y and Li F: The PDK1/c-Jun pathway activated by TGF-β induces EMT and promotes proliferation and invasion in human glioblastoma. Int J Oncol. 53:2067–2080. 2018.PubMed/NCBI
41	Wu W, Chen F, Cui X, Yang L, Chen J, Zhao J, Huang D, Liu J, Yang L, Zeng J, et al: LncRNA NKILA suppresses TGF-β-induced epithelial-mesenchymal transition by blocking NF-κB signaling in breast cancer. Int J Cancer. 143:2213–2224. 2018. View Article : Google Scholar : PubMed/NCBI
42	Ko H, So Y, Jeon H, Jeong MH, Choi HK, Ryu SH, Lee SW, Yoon HG and Choi KC: TGF-β1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 335:205–213. 2013. View Article : Google Scholar : PubMed/NCBI
43	Zeng TD, Zheng B, Zheng W and Chen C: CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1. Eur Rev Med Pharmacol Sci. 22:5928–5937. 2018.PubMed/NCBI
44	Thar Min AK, Okayama H, Saito M, Ashizawa M, Aoto K, Nakajima T, Saito K, Hayase S, Sakamoto W, Tada T, et al: Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Cancer Med. 2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
45	Hong D, Liu T, Huang W, Liao Y, Wang L, Zhang Z, Chen H, Zhang X and Xiang Q: Gremlin1 delivered by mesenchymal stromal cells promoted epithelial-mesenchymal transition in human esophageal squamous cell carcinoma. Cell Physiol Biochem. 47:1785–1799. 2018. View Article : Google Scholar : PubMed/NCBI
46	Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, et al: EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biol Ther. 16:933–940. 2015. View Article : Google Scholar : PubMed/NCBI
47	Wang N, Zhang Z and Lv J: Fentanyl inhibits proliferation and invasion via enhancing miR-302b expression in esophageal squamous cell carcinoma. Oncol Lett. 16:459–466. 2018.PubMed/NCBI